ArticleWorld journal of urology2026
Nomogram for predicting selective renal arterial embolization in post-PCNL hemorrhage among patients with chronic kidney disease.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePercutaneous nephrolithotomy (PCNL) is the standard treatment for large or complex renal calculi; however, postoperative hemorrhage requiring selective renal arterial embolization (SRAE) remains a rare but serious complication. Chronic kidney disease (CKD) may further increase bleeding risk, but predictive models for SRAE in this population are lacking. To develop and validate a nomogram for predicting the need for SRAE in patients with CKD who experience hemorrhage after PCNL.
methodsThis retrospective cohort study included 3153 patients who underwent PCNL in two tertiary hospitals between June 2010 and June 2025. Of these, 986 had CKD. A total of 331 patients with post-PCNL hemorrhage and CKD were analyzed, including 299 who received conservative management and 32 who underwent SRAE. Clinical variables were compared between groups, and independent risk factors were identified using multivariate logistic regression. A nomogram was developed from the significant predictors and validated using receiver operating characteristic (ROC) analysis, calibration curves, and decision curve analysis (DCA).
resultsAmong 331 patients with post-PCNL hemorrhage and CKD, 32 (9.7%) required SRAE. Compared with the conservative group, SRAE patients had a higher rate of prior ipsilateral kidney intervention (31.3% vs. 11.4%), more acute hemorrhage (40.6% vs. 14.4%), and greater hemoglobin drop (39.5 ± 10.7 g/L vs. 25.3 ± 8.8 g/L), and a notably higher proportion of the absence of hydronephrosis (all p < 0.05). Multivariate analysis identified hydronephrosis grade, past ipsilateral intervention, hemorrhage type, and hemoglobin drop as independent predictors of SRAE (p < 0.05). The nomogram incorporating these variables achieved excellent discrimination (AUC = 0.901, C-index = 0.897) and good calibration (Hosmer-Lemeshow, χ² = 6.357, p = 0.607), with robust performance in the external validation cohort (AUC = 0.893). Decision curve analysis demonstrated favorable clinical utility. Among all 3,153 PCNL cases, patients with CKD had a significantly higher incidence of hemorrhage (33.6% vs. 19.3%, p < 0.001), while the SRAE rate was comparable to those with normal renal function (3.2% vs. 2.8%, p = 0.508).
conclusionThe nomogram developed in this study provides a reliable and individualized tool for predicting the need for embolization among CKD patients who have already developed post-PCNL hemorrhage. Incorporating variables such as hemoglobin drop, hemorrhage type, hydronephrosis grade, and prior ipsilateral intervention, this model can assist clinicians in early risk stratification and optimize decision-making for timely intervention.
Indexed as
Identifiers
41553562What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.